KALARIS THERAPEUTICS, INC. Payments of Stock Issuance Costs
KALARIS THERAPEUTICS, INC. (KLRS) reported Payments of Stock Issuance Costs of $1.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-17
- KALARIS THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2020-12-31 was $354.00K.
- KALARIS THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2025 was $1.67M.
- KALARIS THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2020 was $3.47M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|
| 2025-12-31 | $1.67M 10-K · filed 2026-03-17 | ||
| 2020-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $3.47M 10-K · filed 2022-02-10 | |
| 2020-09-30 | $3.12M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |